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Investigating causality in 
associations between smoking 
initiation and schizophrenia using 
Mendelian randomization
Suzanne H. Gage1,2, Hannah J. Jones1,3, Amy E. Taylor1,2, Stephen Burgess1,4, 
Stanley Zammit3,5 & Marcus R. Munafò1,2
Smoking is strongly associated with schizophrenia. Although it has been widely assumed that this 
reflects self-medication, recent studies suggest that smoking may be a risk factor for schizophrenia. 
We performed two-sample bi-directional Mendelian randomization using summary level genomewide 
association data from the Tobacco And Genetics Consortium and Psychiatric Genomics Consortium. 
Variants associated with smoking initiation and schizophrenia were combined using an inverse-
variance weighted fixed-effects approach. We found evidence consistent with a causal effect of smoking 
initiation on schizophrenia risk (OR 1.73, 95% CI 1.30–2.25, p < 0.001). However, after relaxing the 
p-value threshold to include variants from more than one gene and minimize the potential impact 
of pleiotropy, the association was attenuated (OR 1.03, 95% CI 0.97–1.09, p = 0.32). There was little 
evidence in support of a causal effect of schizophrenia on smoking initiation (OR 1.01, 95% CI 0.98–1.04, 
p = 0.32). MR Egger regression sensitivity analysis indicated no evidence for pleiotropy in the effect 
of schizophrenia on smoking initiation (intercept OR 1.01, 95% CI 0.99–1.02, p = 0.49). Our findings 
provide little evidence of a causal association between smoking initiation and schizophrenia, in either 
direction. However, we cannot rule out a causal effect of smoking on schizophrenia related to heavier, 
lifetime exposure, rather than initiation.
It has long been known that smoking is harmful to physical health, but less is known about the nature of its asso-
ciation with mental health. Smoking rates are markedly higher among individuals with mental health disorders 
than in the general population, and while smoking rates have fallen over recent decades, corresponding decreases 
have not been seen in mental health populations1. In particular, smoking is strongly associated with psychotic 
disorders such as schizophrenia2. Historically, up to around 80% of patients with schizophrenia were smokers3, 
and more recent estimates suggest that the prevalence of smoking in inpatients is around 60%4,5. There is evidence 
that supports a self-medication model to explain this association: constituents of tobacco smoke can increase 
the metabolism of anti-psychotic drugs6, and there is also some evidence that nicotine might reduce some of the 
cognitive impairment side effects of drugs such as haloperidol7. Nicotine has also been implicated in improving 
various physiological deficits associated with schizophrenia, including pre-pulse inhibition8 and the P50 wave9.
Recently, however, some evidence has emerged to suggest that the association between smoking and schizo-
phrenia could be operating in the opposite direction. A systematic review and meta-analysis of cross sectional and 
prospective studies of smoking and psychotic outcomes indicated that daily tobacco use was associated with both 
an increased risk of psychosis, and earlier age of onset of a disorder10 – although this study did not address con-
founding presenting only unadjusted estimates. A recent large prospective study of Swedish registry data similarly 
found that light and heavy cigarette smoking was associated with incident risk of schizophrenia11. The association 
was dose-dependent, and persisted (though was attenuated) after adjustment for socioeconomic status, drug 
use and degree of familial genetic overlap. Perhaps most interestingly, in a recent genomewide association study 
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(GWAS) of schizophrenia12, a variant (rs8042374) within the CHRNA5-A3-B4 gene cluster strongly associated 
with heaviness of smoking in smokers (p = 2.4 × 10−24 in the cigarettes-per-day GWAS13) was one of the variants 
to reach genomewide significance. This could mean that there is shared genetic architecture between schizo-
phrenia and smoking, but it could also indicate a causal association between smoking and schizophrenia14,15. It is 
plausible that the association could be causal in either or both directions, but this is very hard to establish using 
standard observational epidemiological methods. For example, an earlier Swedish longitudinal study found evi-
dence of an association in the opposite direction to the study discussed above16.
One approach to investigate causality in observational studies is Mendelian randomization (MR), whereby 
genetic variants that predict an observational exposure are used as unconfounded proxy measures for the expo-
sure itself. Associations between the variants and the outcome of interest can thus provide evidence of causation 
whilst, subject to certain assumptions, eliminating problems of confounding and reverse causation. A recent 
Mendelian randomization study found an association between a SNP in the nicotinic acetylcholine receptor alpha 
3 subunit (CHRNA3) gene strongly associated with heaviness of smoking (rs1051730) and likelihood of being pre-
scribed anti-psychotic medication, which was used as a proxy for risk of schizophrenia, in a sample of smokers17.
Since genetic variants typically explain a small proportion of the variance in the exposure, very large sample 
sizes are needed, which can make conducting such studies challenging. Recently, the two-sample MR method has 
been developed, whereby data on gene-exposure and gene-outcome associations from different samples can be 
used to conduct MR analyses18. This means that publicly-available summary data from genomewide association 
studies can be used to assess causal associations between exposures and outcomes, increasing sample size, and 
therefore power to detect causal associations.
We used two-sample MR to assess the causal effect of smoking initiation on schizophrenia (using genetic 
variants associated with smoking initiation), and of schizophrenia risk on smoking initiation, cigarettes per day, 
and cessation (using genetic variants associated with schizophrenia risk), in an attempt to clarify the causal rela-
tionship between smoking and schizophrenia.
Results
Schizophrenia risk and smoking initiation. The 94 SNPs used as a proxy for risk of schizophrenia case 
status provided little evidence of a causal effect of schizophrenia risk on likelihood of being a smoker (OR per 
1 unit increase in log odds of schizophrenia 1.02, (95% CI 0.98–1.06, p = 0.32). This translates to an odds ratio 
of 1.01 (95% CI 0.98–1.04) for smoking per doubling of odds of schizophrenia (see Fig. 1). There was moderate 
heterogeneity (I2  =  38%, 95% CI 20–52% p = 0.0002), but the random-effects estimate was very similar to the 
fixed effects model (OR 1.01, 95% CI 0.98–1.05, p = 0.37). When we performed MR Egger regression, there was 
no evidence that the intercept (representing bias in the causal estimate due to pleiotropy) differed from the null 
(intercept OR 1.01, 95% CI 0.99–1.02, p = 0.49). The slope point estimate (representing the causal effect estimate 
of schizophrenia on smoking initiation) did not statistically differ from the null (OR 0.95, 95% CI 0.78–1.16, 
p = 0.61).
Schizophrenia risk and other smoking phenotypes. The 94 SNPs used as a proxy for risk of schizo-
phrenia case status provided little evidence of a causal effect of schizophrenia risk on smoking heaviness in 38,181 
daily smokers in the TAG consortium (OR per unit increase in log odds of schizophrenia 1.03; 95% CI 0.86–1.24, 
p = 0.76). There was also little evidence of a causal effect of schizophrenia risk on odds of smoking cessation 
among 35,845 smokers in the TAG consortium (OR 0.97; 95% CI 0.93–1.03, p = 0.22).
Smoking initiation and schizophrenia risk. The 4 SNPs used as a proxy for likelihood of being an ever 
smoker provided some evidence of a causal effect of smoking status on risk of schizophrenia (OR per 1 unit 
increase in log odds of being a smoker 2.17; 95% CI 1.46–3.23, p < 0.001). This equates to an odds ratio of 1.71 
(95% CI 1.30–2.25) of schizophrenia per doubling in odds of smoking. When only the most strongly associated 
SNP (rs6265) was analysed, the association was similar (OR 1.98; 95% CI 1.03–3.58) Due to the correlated nature 
of the SNPs, it was not possible to perform MR Egger regression as a sensitivity analysis to test the assumption of 
no biological pleiotropy.
Using genetic variants associated with smoking initiation at a less stringent significance threshold, 21 addi-
tional independent SNPs associated with smoking initiation (at p < 10−6) provided no evidence of a causal effect 
of smoking status on risk of schizophrenia (OR per doubling in odds of being a smoker including one BDNF 
SNP (rs6265) OR 1.03; 95% CI 0.97–1.09, p = 0.32). Heterogeneity in this analysis was somewhat large, (I2 = 61.3, 
95% CI 38–76%, p < 0.001). However, MR Egger regression suggested no evidence of pleiotropy (intercept OR 
1.03, 95% CI 1.00–1.06, p = 0.061), and weak evidence of causality (slope OR 0.69, 95% CI 0.43–1.08, p = 0.118). 
Results were similar if we excluded rs6265.
Discussion
Schizophrenia risk and smoking initiation. Our results did not support a possible causal effect of schizo-
phrenia risk on smoking initiation. Sensitivity analyses suggested that although there was some heterogeneity in the 
results, there was no clear evidence for biological pleiotropy impacting on the findings, meaning that bias due to vio-
lation of one of the key assumptions of MR (i.e., that any genetic effect on the outcome only occurs via the exposure, 
and not directly) was unlikely to be substantial. The MR Egger regression causal estimate did not differ from the null. 
Although the point estimate was in the opposite direction, the confidence intervals were consistent with our main 
findings.
Smoking initiation and schizophrenia risk. When using only genomewide significant SNPs, our results 
were consistent with a possible causal effect of smoking initiation on schizophrenia risk. However, this result was 
somewhat hard to interpret as only four SNPs were used in this risk score, and all of these were from the same 
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Figure 1. Forest plot showing association with smoking initiation (odds ratio and 95% confidence interval) 
for each genomewide-significant schizophrenia SNP. 
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gene region (BDNF). These SNPs are all highly correlated, and although correlation was taken in to account in 
the MR model, the risk of biological pleiotropy (i.e., an effect of gene on the outcome not via smoking) was much 
harder to rule out; BDNF and its associated SNPs have reached genomewide significance in a number of other 
GWAS, including those of obesity and body mass index19,20, and caffeine consumption21.
Although no SNPs in BDNF reach genomewide significance in the schizophrenia GWAS, it is a gene that has 
been implicated in schizophrenia previously, particularly in relation to cognitive deficits associated with the dis-
ease22, as well as other psychiatric disorders23. Some studies have suggested that smoking might be a method by 
which people with schizophrenia alleviate cognitive difficulties, although other studies suggest cognition is worse 
in people with schizophrenia who smoke24. Furthermore, given the higher prevalence of smoking in populations 
with mental health problems, it is possible that the smoking initiation GWAS sample might be enriched for men-
tal health problems compared to the general population, meaning that variants identified could be causally linked 
to these mental health problems rather than smoking. This result must therefore be interpreted with particular 
caution; the association between SNPs in the BDNF gene area and schizophrenia may reflect a causal association 
between smoking initiation and schizophrenia, but could also potentially be a pleiotropic effect, either via one 
of the already identified alternative pathways such as obesity or caffeine, or via another currently unidentified 
pathway. It was not possible to conduct an MR Egger regression using these 4 SNPs to test whether these smoking 
initiation SNPs were causally related to schizophrenia due to the high correlation between the smoking SNPs, and 
the small number of them.
Our analysis using a lower p-value cutoff found no evidence for an association between smoking initiation 
and risk of schizophrenia, and this also supports the interpretation that this was a pleiotropic effect, although in 
2-sample MR, the use of weaker instruments such as these can result in bias towards the null.
Smoking heaviness phenotype. We did not use cigarettes per day or smoking cessation SNPs as exposure 
variables, as we could not stratify these data by smoking status. The SNP that strongly predicts cigarettes per day 
(rs1051730) does not predict smoking initiation, and only exerts an effect on smoking heaviness after a person 
has become an established smoker25. The GWAS that identified it was conducted in a sample of daily smokers, 
unlike that for smoking initiation which was a sample that included ever smokers and never smokers13. This 
genetic variant has been shown to be associated with schizophrenia risk as a highly correlated SNP (rs8042374) 
reached genomewide significance in the PGC2 GWAS of schizophrenia12 (used in these analyses), suggesting a 
possible causal role of smoking heaviness on schizophrenia. However, as the analysis in the current study is based 
on summary data, we cannot stratify the sample to investigate whether this association is seen in non-smokers 
(indicating shared genetic aetiology of the two traits) or only in regular smokers (indicating a direct causal asso-
ciation). Whilst this SNP has been identified in unstratified GWAS of outcomes where a causal association with 
smoking is known (e.g., lung cancer), this has only been the case where effect sizes are sufficiently large that the 
association can survive this dilution. In order to glean more information about causality (versus direct biological 
pleiotropy, where the SNP in question has an effect on both smoking and schizophrenia), a stratified analysis 
would be required, to check for a lack of association in non-smokers. To perform a 2-sample analysis on the 
unstratified PGC2 GWAS would merely repeat what is already known from the GWAS, that this SNP is associated 
with schizophrenia risk, but would not help us understand causality.
Strengths and limitations. One strength of two-sample MR is that it offers very large sample sizes for 
analyses. Our analyses in both directions are based on such samples, which should provide sufficient power to 
identify small effects that are likely in the context of complex phenotypes such as schizophrenia risk and smoking 
initiation. However, even in these designs we are still underpowered to detect extremely small effect sizes given 
the small amount of variance explained by the SNPs we have used. For example, rs6265 explains 0.03% of the 
variance in smoking initiation, meaning we have approximately 86% power to detect an effect size of OR 1.1 of 
smoking initiation on schizophrenia risk.
It is important to note that the genetic risk for schizophrenia is based on a case-control GWAS, and therefore 
this might affect our interpretation of the association between schizophrenia and smoking. Schizophrenia is a rare 
outcome, and most of the TAG sample will not have schizophrenia. Therefore, we are making an assumption here 
that genetic risk for schizophrenia might be inducing subclinical schizophrenia symptoms in those that do not 
reach clinical diagnosis. There is some evidence that this is the case26, though it is not yet strong or consistent27.
A further potential limitation could be the role of maternal smoking, as this may be a genetic confounder, 
influencing both the genotype of the individual, and the relationship between smoking and schizophrenia in the 
individual. However, the impact of maternal smoking would need to be substantial in order to affect this analysis, 
given that smoking initiation is independent from smoking during pregnancy and therefore likely influenced by 
different genetic variants13, and offspring share on average 50% of their genotype with their mothers.
One final potential limitation of this study is the possibility of population stratification due to the different 
ancestry samples included in the PGC2 GWAS (both European and Asian). There is some evidence of a slight 
difference in allele frequency for rs6265 between European and Asian populations (A allele frequency 0.2 in 
Europeans and 0.4 in Asians according to hapmap)28. The PGC2 GWAS adjusted for principal components, which 
should mitigate the effect of population stratification somewhat.
The association between smoking, schizophrenia and other childhood mental health is likely to be complex, 
in terms of both environmental and genetic risk factors. Childhood mental health predicts both smoking and risk 
of schizophrenia. Therefore the impact of different forms of pleiotropy on the associations between schizophrenia 
and smoking is important to consider. While biological pleiotropy (where one variant has multiple independent 
effects on different phenotypes) violates the assumptions of MR, mediated pleiotropy (where one variant influ-
ences a phenotype via intermediate mechanisms upstream of that phenotype) is not so problematic. For example, 
smoking could influence adolescent mental health, which could in turn increase the risk of more serious mental 
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health problems such as schizophrenia. This would still be consistent with a causal effect of smoking on schizo-
phrenia. We conducted MR Egger regressions to formally test for biological pleiotropy, and found little evidence 
for this in either direction.
Comparison to previous literature. Although the evidence from this study for smoking initiation as a risk 
factor for schizophrenia is weak, other studies posit this as a plausible explanation for high rates of smoking seen 
in individuals with schizophrenia. Given that there are very few modifiable risk factors presently identified for 
this hugely debilitating disease further investigation of this question is therefore warranted. Stronger evidence to 
support or refute a causal effect of smoking might also inform our understanding of the relationship between can-
nabis use and schizophrenia, given the common co-occurrence of cannabis and tobacco use29; however, it seems 
highly unlikely that smoking could explain this association given that psychotic experiences are often described 
during acute intoxication with cannabis, but not with tobacco.
In order to determine whether the association between smoking and schizophrenia is causal, conventional 
MR using SNPs associated with heaviness of smoking would be informative, if a large sample could be identified 
with information on both schizophrenia case status and smoking status. One study has attempted this using 
anti-psychotic medication as a proxy for schizophrenia17. They found weak evidence using MR that higher ciga-
rette consumption amongst smokers was associated with increased likelihood of being on antipsychotic medica-
tion, although it is not possible to rule out a direct effect of the SNP (rs1051730) on the outcome from these data. 
In that study, the OR was substantially smaller in their sample of non-smokers, although confidence intervals 
overlapped substantially between the two analyses. It is also important to note that many individuals who are 
prescribed anti-psychotic medication do not have schizophrenia or a psychotic illness, and therefore this may not 
be an ideal proxy measure for schizophrenia30.
We found little evidence that schizophrenia risk was associated with uptake of smoking. This is in contrast to 
previous suggestions that the association between smoking and schizophrenia could be due to self-medication 
with nicotine. Evidence from observational epidemiology is broadly consistent with our present findings, namely 
that smoking initiation appears to predate psychotic experiences or schizophrenia31. Our findings are also con-
sistent with a study that used cross-trait LD-score regression to examine the genetic correlation between smok-
ing initiation and schizophrenia32. This study found no evidence of a genetic correlation, although it did find 
weak evidence of associations between schizophrenia and age of smoking initiation, and cigarettes per day. MR 
analyses are more suited to assessing causality than LD-score regression (which targets genetic correlation). MR 
uses variants identified as being good proxies for modifiable risk factors to provide a directional estimate of 
the association between the risk factor and the outcome. In contrast, LD-score analysis uses variants across the 
whole genome and is a symmetric (i.e., non-directional) analysis of the risk factor and the outcome, meaning 
that LD-score regression is not able to ascertain the direction of causation between the risk factor and outcome. 
Also, the contribution of a variant to a MR analysis is proportional to its association with the exposure, whereas 
the contribution of a variant to LD-score regression is proportional to its “LD-score”. This means that even if a 
MR investigation was undertaken using genetic variants from the whole genome, it would differ from LD-score 
regression. The LD-score does not differ between exposures, meaning there is the potential for systematic bias in 
LD-score regressions across different phenotypes. Finally, the LD-score is likely to be a weak instrument, meaning 
a higher possibility of bias.
In conclusion, we found little evidence to suggest that schizophrenia risk increases the likelihood of smok-
ing initiation. Our results provide some evidence consistent with a causal effect of smoking on schizophrenia, 
although a sensitivity analysis where we relaxed the p-value threshold suggested this association could be due to 
pleiotropy, i.e. that smoking initiation and schizophrenia risk share genetic aetiology, rather than being causally 
related. Nevertheless, while the current evidence that smoking might be a risk factor for schizophrenia is not 
compelling, the potential that smoking could be a modifiable risk factor for schizophrenia is a strong driver for 
further investigation of this question.
Methods
Single nucleotide polymorphisms (SNPs) associated with smoking initiation, and schizophrenia risk, were iden-
tified from genomewide significant hits in the Tobacco And Genetics (TAG) consortium13 and the Psychiatric 
Genetics Consortium (PGC2)12 GWAS, respectively.
SNPs associated with schizophrenia. A GWAS meta-analysis conducted by the PGC identified 128 
independent SNPs (in 108 physically distinct loci) that met genomewide significance (p < 5 × 10−8) for schiz-
ophrenia risk in a sample of 36,989 schizophrenia cases and 113,075 controls. These SNPs explained approxi-
mately 3.4% of the variance in schizophrenia risk. There were 51 SNPs from PGC2 that were genotyped in TAG. 
SNP Chromosome Position
Gene 
region
Reference 
allele
Ref allele 
frequency
Smoking Initiation Schizophrenia
Beta SE p Beta SE p
rs6265 11 27636492 BDNF T 0.21 − 0.061 0.011 1.8 × 10−8 − 0.052 0.013 8 × 10−5
rs4923460 11 27613365 BDNF T 0.23 − 0.058 0.011 4.1 × 10−8 − 0.045 0.013 4.2 × 10−4
rs1304100 11 27528179 BDNF A 0.74 0.055 0.01 4.4 × 10−8 0.038 0.013 2.7 × 10−3
rs6484320 11 27659764 BDNF A 0.76 0.057 0.01 4.9 × 10−8 0.043 0.013 7.5 × 10−4
Table 1.  List of the SNPs associated with smoking initiation used in the 2-sample analysis, and their 
associations with smoking initiation, and with schizophrenia.
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We used SNAP (https://www.broadinstitute.org/mpg/snap/) and the PhenoScanner tool33 to identify proxies in 
high linkage disequilibrium (r2 > 0.9), and were able to find an additional 43 proxy SNPs that were in TAG (see 
Supplementary Table 1), so that the total number of SNPs for our analysis was 94 (out of a possible 108).
SNPs associated with smoking initiation. The TAG conducted a GWAS of smoking behaviour on 
74,053 individuals, and a replication sample of over 140,000 individuals. A binary ever/never measure of smoking 
initiation was used as our exposure of interest as opposed to smoking heaviness, as smoking heaviness requires 
knowledge of participants’ smoking status, which was not available in the PGC2 summary data. Eight SNPs met 
genomewide significance (p < 5 × 10−8) for smoking initiation, all located in the BDNF gene region. A number 
of these SNPs were in very high linkage disequilibrium with each other. Using r2 values obtained from SNAP we 
identified all pairs of SNPs correlated at ≥ 0.9 and randomly selected one from each pair to keep, dropping the 
others from the score in a stepwise manner. Very highly correlated SNPs do not give extra information, but can 
make the model unstable. The remaining four SNPs (see Table 1) were also correlated, so a correlation matrix was 
created (see Supplementary Table 2) which required modification of the likelihood-based method for estimation 
of a causal effect (see below)18. Given the correlation between these SNPs, we conducted two sensitivity analyses 
around this question. Firstly, we ran the analysis with only the most strongly associated SNP (rs6265). Secondly, 
we identified a further 21 independent SNPs (see Supplementary Table 3) associated with smoking initiation at 
a slightly lower threshold (p < 10−6). A correlation matrix was not required for this analysis, as all SNPs were 
independent of each other. Although relaxing the p-value threshold may introduce more weak instruments in 
to our analysis, the inclusion of several independent SNPs means pleiotropy is potentially less likely, as in order 
to pleiotropy to impact, all pleiotropic effects would have to operate in the same direction, which is implausible. 
It also allows us to be able to undertake MR Egger regression as a sensitivity analysis to more formally assess the 
impact of biological pleiotropy on the association.
Statistical analysis. Schizophrenia risk on smoking initiation, cigarettes per day, and smoking cessation. Log 
odds ratios and standard errors for the SNPs associated with schizophrenia were recorded. These SNPs were then 
identified in the full genomewide results from the TAG consortium for each phenotype, and beta-coefficients and 
standard errors recorded. The SNP-exposure and SNP-outcome associations for the 94 SNPs present in the PGC2 
and TAG GWAS were combined in a fixed effects meta-analysis using an inverse-variance weighted approach. 
This is equivalent to a weighted regression of the SNP-outcome coefficients on the SNP-exposure coefficients. 
The results of this analysis were converted to odds ratios, and the resulting output is the odds ratio for smoking 
initiation, cigarettes per day, and cessation (as appropriate) per unit increase in the log odds ratio of schizophrenia 
risk. This is somewhat hard to interpret, so ORs were converted (by multiplying by 0.693) in order to represent the 
odds ratio per doubling in odds of the binary exposure.
Smoking initiation on schizophrenia risk. Beta coefficients and standard errors for the four remaining SNPs 
associated with smoking initiation were recorded from the TAG dataset. These SNPs were identified in the full 
genomewide results from the PGC2, and log odds ratios and standard errors recorded. The SNP-exposure and 
SNP-outcome associations were combined using the same method as above, but further developed to allow for 
consideration of the correlational structure between the SNPs. Again the output was converted to odds ratio, and 
can be interpreted as the effect on schizophrenia risk per unit increase in the log odds ratio of smoking initiation, 
then converted to represent an odds ratio for schizophrenia risk per doubling in odds to smoking initiation.
Sensitivity analyses. In order to formally test for potential violations of Mendelian randomization assumptions, a 
number of sensitivity analyses were undertaken. I2 statistics were calculated to estimate heterogeneity. We also ran 
a random-effects model to account for heterogeneity, and performed MR Egger regression34. This latter method 
relaxes the assumption made in MR that the effects of genetic variants on the outcome are entirely mediated 
via the exposure. This is achieved by allowing an intercept term in the weighted regression of the SNP-outcome 
coefficients on the SNP-exposure coefficients. The intercept parameter represents the average pleiotropic effect of 
a SNP on the outcome (the direct effect on the outcome not via the exposure of interest). This intercept value can 
therefore provide a test of directional pleiotropy; if the intercept term is close to the null, then bias in the causal 
estimate due to pleiotropy is less likely. The beta coefficient from this regression provides a consistent estimate 
of the causal effect under the assumption that the pleiotropic effects on SNPs on the outcome are uncorrelated 
with the associations of the SNPs with the exposure. Due to the small number of SNPs, and the high correlation 
between them, MR Egger regression could not be performed for the association of smoking initiation on schizo-
phrenia using the SNPs associated at a genomewide level, so we used the 21 additional SNPs at the less stringent 
p-value threshold for this analysis.
Sample overlap. Two-sample Mendelian randomization assumes that there is no overlap of participants between 
the two data sources used. Both TAG and PGC2 used MIGen data, making up 3.6% of the TAG consortium, and 
1.4% of the PGC2 sample. This is not substantial, and any bias from this is likely to be in the direction of the null35.
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